HK1051856A1 - A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor - Google Patents

A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor

Info

Publication number
HK1051856A1
HK1051856A1 HK03102573A HK03102573A HK1051856A1 HK 1051856 A1 HK1051856 A1 HK 1051856A1 HK 03102573 A HK03102573 A HK 03102573A HK 03102573 A HK03102573 A HK 03102573A HK 1051856 A1 HK1051856 A1 HK 1051856A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
HK03102573A
Other languages
English (en)
Inventor
Erik Christopher Chelius
Susan Marie Reutzel-Edens
Sharon Van Den Berghe Snorek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1051856(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1051856A1 publication Critical patent/HK1051856A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HK03102573A 2000-02-25 2003-04-09 A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor HK1051856A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (fr) 2000-02-25 2001-02-12 Nouvelle forme cristalline de n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-acide glutamique et procede correspondant

Publications (1)

Publication Number Publication Date
HK1051856A1 true HK1051856A1 (en) 2003-08-22

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102573A HK1051856A1 (en) 2000-02-25 2003-04-09 A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor

Country Status (36)

Country Link
US (1) US7138521B2 (fr)
EP (1) EP1259513B1 (fr)
JP (1) JP4846158B2 (fr)
KR (1) KR100744917B1 (fr)
CN (1) CN1183135C (fr)
AR (1) AR029471A1 (fr)
AT (1) ATE249462T1 (fr)
AU (1) AU777047B2 (fr)
BR (1) BR0108604A (fr)
CA (1) CA2400155C (fr)
CO (1) CO5261585A1 (fr)
CZ (1) CZ303772B6 (fr)
DE (1) DE60100750T2 (fr)
DK (1) DK1259513T3 (fr)
DZ (1) DZ3283A1 (fr)
EA (1) EA004684B1 (fr)
EG (1) EG24073A (fr)
ES (1) ES2206403T3 (fr)
HK (1) HK1051856A1 (fr)
HR (1) HRP20020701B1 (fr)
HU (1) HU229704B1 (fr)
IL (2) IL150480A0 (fr)
MX (1) MXPA02008242A (fr)
MY (1) MY124784A (fr)
NO (1) NO323422B1 (fr)
NZ (1) NZ519796A (fr)
PE (1) PE20011082A1 (fr)
PL (1) PL208061B1 (fr)
PT (1) PT1259513E (fr)
SI (1) SI1259513T1 (fr)
SK (1) SK287375B6 (fr)
SV (1) SV2002000321A (fr)
TW (1) TWI237024B (fr)
UA (1) UA72791C2 (fr)
WO (1) WO2001062760A2 (fr)
ZA (1) ZA200205265B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
EP1954284A4 (fr) * 2005-11-04 2010-01-06 Merck & Co Inc Traitement anticancereux au saha et au pemetrexed
EP1942907A2 (fr) * 2005-11-04 2008-07-16 Merck and Co., Inc. Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer
EP1934226A2 (fr) 2006-08-14 2008-06-25 Sicor, Inc. Diacide de pemetrexed de haute pureté et ses procédés de préparation
TWI374886B (en) 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
US8629152B2 (en) * 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP2322526A1 (fr) * 2006-08-14 2011-05-18 Sicor, Inc. Forme cristalline de diacide de pemetrexed et son procédé de préparation
AU2007317921A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using SAHA and Bortezomib for treating multiple myeloma
WO2008124485A2 (fr) * 2007-04-03 2008-10-16 Dr. Reddy's Laboratories Ltd. Formes solides de pemetrexed
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (fr) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Forme amorphe stable de Pemextred disodium
WO2010028105A2 (fr) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Disodium de pemetrexed amorphe
WO2010030598A2 (fr) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques comprenant du pemetrexed
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
EP2504341A1 (fr) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG Nouvelle forme cristalline du pemetrexed disodique
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
CA2827455C (fr) * 2011-03-25 2017-10-24 Scinopharm Taiwan Ltd Procede pour la production d'un sel de pemetrexed
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (fr) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Procédé de préparation de dipotassium de pemetrexed cristallin
ZA201400898B (en) 2013-02-06 2015-12-23 Cipla Ltd Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
WO2014167585A1 (fr) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Formulation de pemetrexed
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
WO2014198338A1 (fr) 2013-06-14 2014-12-18 Synthon B.V. Sel d'arginine du pémétrexed stable et compositions le comprenant
EP3021849B1 (fr) 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Nouvelles formes cristallines de sels de trométhamine de pemetrexed
DK3040074T3 (en) 2013-10-03 2018-10-08 Fujifilm Corp INJECTION PREPARATION AND METHOD OF PREPARING IT
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
EP3212193A4 (fr) 2014-10-30 2018-08-01 ScinoPharm Taiwan, Ltd. Formes cristallines du diacide de pémétrexed et leurs procédés de production
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
CN109906071A (zh) * 2017-10-10 2019-06-18 太阳制药工业公司 培美曲塞的静脉输注剂型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
EP0923287A4 (fr) * 1996-08-30 2001-08-01 Lilly Co Eli Antifoliques non classiques de pyrrolo 2,3-d]pyrimidine
CN1213998C (zh) * 1997-09-26 2005-08-10 伊莱利利公司 用于制造抗叶酸剂的方法和中间体
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
EP1212325A2 (fr) * 1999-08-23 2002-06-12 Eli Lilly And Company Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo 2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation

Also Published As

Publication number Publication date
CA2400155C (fr) 2009-09-15
AU777047B2 (en) 2004-09-30
DE60100750D1 (de) 2003-10-16
PE20011082A1 (es) 2001-10-22
EA004684B1 (ru) 2004-06-24
CO5261585A1 (es) 2003-03-31
PL208061B1 (pl) 2011-03-31
ATE249462T1 (de) 2003-09-15
HUP0204232A3 (en) 2006-01-30
AR029471A1 (es) 2003-07-02
WO2001062760A3 (fr) 2001-12-06
EG24073A (en) 2008-05-11
DK1259513T3 (da) 2004-01-12
JP2003530321A (ja) 2003-10-14
MXPA02008242A (es) 2002-11-29
SK11862002A3 (sk) 2003-01-09
CZ20022875A3 (cs) 2003-02-12
EA200200905A1 (ru) 2003-02-27
SI1259513T1 (en) 2003-12-31
UA72791C2 (uk) 2005-04-15
CA2400155A1 (fr) 2001-08-30
MY124784A (en) 2006-07-31
NO20023974D0 (no) 2002-08-21
PL356423A1 (en) 2004-06-28
NZ519796A (en) 2003-01-31
ZA200205265B (en) 2003-11-11
JP4846158B2 (ja) 2011-12-28
DZ3283A1 (fr) 2001-08-30
AU3445101A (en) 2001-09-03
PT1259513E (pt) 2004-02-27
US7138521B2 (en) 2006-11-21
WO2001062760A2 (fr) 2001-08-30
HRP20020701B1 (en) 2011-02-28
NO20023974L (no) 2002-08-21
SV2002000321A (es) 2002-07-16
KR100744917B1 (ko) 2007-08-01
HU229704B1 (en) 2014-05-28
CN1406238A (zh) 2003-03-26
BR0108604A (pt) 2002-11-19
ES2206403T3 (es) 2004-05-16
HRP20020701A2 (en) 2003-12-31
IL150480A (en) 2007-12-03
EP1259513A2 (fr) 2002-11-27
CZ303772B6 (cs) 2013-05-02
DE60100750T2 (de) 2004-07-29
KR20020075449A (ko) 2002-10-04
TWI237024B (en) 2005-08-01
EP1259513B1 (fr) 2003-09-10
NO323422B1 (no) 2007-04-30
US20030216416A1 (en) 2003-11-20
SK287375B6 (sk) 2010-08-09
HUP0204232A2 (hu) 2003-04-28
IL150480A0 (en) 2002-12-01
CN1183135C (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
HK1051856A1 (en) A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
PT1155015E (pt) Processo para a preparação de (e)-(6-¬2-¬4-(4-fluorofenil)-6- isopropil-2-¬metil(metilsulfonil)amino pirimidin-5-il vinil(4r,6s)-2,2-dimetil¬1,3 dioxan-4-il)acetato de terc-butilo
HK1081527A1 (en) Processes for the preparation of 4-[4-[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
CA2031890A1 (fr) Derives de l'acide n-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)glutamique
AU7288100A (en) Regulation of secondary metabolite production
HUP0402129A3 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives, preparation thereof, compositions containing the same and processes for their use
HUP0402253A3 (en) Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
WO2001017959A3 (fr) Antagonistes du recepteur de la vitronectine
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
IL157061A (en) Process and intermediates for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl)piperazin -1-yl)-methanone and salts thereof
AU2001296746A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
PL346805A1 (en) Method of obtaining novel derivatives of pyridine, method of obtaining hydroxy-substituted derivatives of pyridine, method of obtaining derivatives of oxiranylpyridine, novel derivatives of 3-(1,2=dihydroxyethyl)pyridine, novel derivatives of 2-pyridin-3-yl-2-hydroxyethylenic ester, novel derivatives of pyridine, novel derivatives of (di)oxydioxathiolanylpyridine, novel derivatives of t-butyl[2r-4-aminofhenyl)ethyl]-[2-hydroxy-2-pyridin-3-ylethyl]carbaminic ester, novel derivatives of t-butyl[2r-4-aminophenyl)ethyl]-[2-(tert-butylodimethylsilanyloxy)-2-pyridin-3-ylethyl]carbaminic ester, [2r-4-aminopyhenyl)ethyl]-[2-(tert-butylodimethylsilanyloxy)-2-(6-chloropyridin-3-yl)ethyl]-[-2-(nitrophenyl)ethyl]carbaminic ester and novel derivatives of 3-{1-tert-butylodimethylsilanyloxy)-2-[[2--(nitrophenyl)ethyl]amino]ethyl}pyridine
PL337788A1 (en) Method of obtaining 1-{[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazole[3,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl}-4-methylpiperazine
WO2003104211A3 (fr) Dichlorhydrate cristallin d'acide acetique [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl] ethoxy]
SI1265856T1 (en) Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
HK1090046A1 (en) Tetrahydro-4h-pyrido [1, 2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
AU2002230022A1 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
AU2002302635A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof
AU2002255007A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180212